Literature DB >> 2785991

Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus.

S D Gowda1, B S Stein, E G Engleman.   

Abstract

We have used a recombinant vaccinia virus (VV) which expresses high levels of human immunodeficiency virus-1 (HIV-1) gag proteins to analyze the processing pathway of the gag p55 precursor. HIV-1 gag proteins were isolated from [3H]leucine-labeled VV:gag-infected H9 T lymphocytes by immunoprecipitation with either anti-p24, anti-p17, or anti-p6 antibodies. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis revealed that processing of the p55 precursor involves three major intermediates (p41a, p41b, and p39). The p41a and p39 proteins contain the p17 and p24 protein segments, and the p41b is comprised of p24 and p15 segments. On two-dimensional gels, each intermediate as well as the mature p24 and p17 proteins migrated as distinct species. [3H]Myristic acid labeling of the HIV-1 gag proteins revealed that in addition to p55 and p17, the p41a and p39 intermediates, but not p41b, are myristylated, confirming that myristylation occurs at the NH2 terminus before cleavage of the p55 precursor protein. We conclude that the myristylated HIV-1 gag p55 precursor is initially cleaved at random either at the p17/p24 junction or at two sites between p24 and p15 proteins, resulting in three intermediates (p41a, p41b, and p39) which are subsequently cleaved to yield mature gag proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785991

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

Authors:  A H Kaplan; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

4.  Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.

Authors:  R J Tritch; Y E Cheng; F H Yin; S Erickson-Viitanen
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Compensatory point mutations in the human immunodeficiency virus type 1 Gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication.

Authors:  C Liang; L Rong; M Laughrea; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

6.  HIV-1 protease inhibits its homologous reverse transcriptase by protein-protein interaction.

Authors:  M Böttcher; F Grosse
Journal:  Nucleic Acids Res       Date:  1997-05-01       Impact factor: 16.971

7.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

8.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria.

Authors:  J Luban; C Lee; S P Goff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.